Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Accuryn Medical

Request full access

Patient monitoring platform that detects sepsis and fluid overload in ICU patients via urinary catheter

Hayward, United StatesFounded 2011Biotech & Life Sciences

About Accuryn Medical

Accuryn Medical, formerly known as Potrero Medical Inc., is a predictive health company founded in 2011 and headquartered in Hayward, California. The company emerged from the medical device incubator Theranova, with a focus on addressing significant challenges in healthcare. A key milestone was the successful restructuring and completion of an over-subscribed equity offering in early 2024, which provided a clean balance sheet and substantial funding.

The company operates in the critical care monitoring market, providing a solution to the challenges of Acute Kidney Injury (AKI), a condition affecting a large percentage of ICU patients and responsible for significant mortality and healthcare costs. Accuryn's business model centers on selling its proprietary monitoring system to hospitals and critical care units. The company's revenue is generated from these sales, and it has shipped over 100,000 catheters nationwide. Leadership has seen recent transitions, with Rich Keenan and Sanjay Banerjee appointed as Co-CEOs in April 2024, followed by Todd Dunn, a former customer with a background at GE Healthcare and Atrium Health, taking the CEO role.

Accuryn Medical's core product is the Accuryn® Monitoring System, which transforms a standard Foley catheter into a smart-sensing diagnostic tool. This system provides real-time, continuous monitoring of vital signs including urine output (UO), intra-abdominal pressure (IAP), and core body temperature. A key feature is its active drain line clearance, which automatically prevents blockages to ensure accurate UO measurement, a critical factor in detecting kidney distress. The system received FDA 510(k) clearance in 2016 and the CE Mark in Europe in 2019. Further enhancing its capabilities, the FDA granted Breakthrough Device Designation in 2022 for the company's AKI Predict machine learning algorithm, designed for the advanced prediction of AKI. This allows the system to provide alerts for potential kidney injury hours earlier than traditional methods like serum creatinine tests, enabling earlier clinical intervention.

Source: Dealroom company data

At a glance

Status
Operational
Employees
38
Open positions
None listed
Dealroom signal
70.9/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Predictive Analytics, Biotechnology, Kidney
Technology
Artificial Intelligence, Big Data, Deep Tech, Machine Learning, Nanotech, Recognition Technology
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing May 2026 $6.5M $133M Undisclosed ↗
LATE VCOther financing Apr 2023 $18M $71M Undisclosed ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Accuryn Medical website traffic

Latest recorded traffic for Accuryn Medical is 3.4K monthly website visits, down 5.6% over the last three months. Accuryn Medical's team grew 2.7% over the past year.

Latest monthly visits3.4K 3-month web change-5.6% 1-year team growth+2.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Accuryn Medical in the Hayward ecosystem

Live from Dealroom

The Accuryn Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Green Park & Golf Ventures

Series B and later3 investors entered at this stage

  • GT Healthcare
  • Sonder Capital
  • Sonder
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Accuryn Medical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Accuryn Medical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.